DATE14 Jul

NIFTY 24,052 ▼ 0.66%BANK NIFTY 57,462 ▼ 1.15%NIFTY IT 28,725 ▼ 1.00%NIFTY PHARMA 25,907 ▲ 1.03%NUVOCO 341 ▲ 7.85%AEGISVOPAK 281 ▼ 7.47%BIOCON 437 ▲ 6.41%CONCOR 493 ▲ 6.29%NEWGEN 554 ▼ 6.11%THERMAX 4,380 ▼ 6.09%WELSPUNLIV 165 ▼ 5.51%AEGISLOG 1,222 ▼ 5.50%ADANIPOWER 226 ▲ 4.97%MRPL 157 ▼ 4.72%NIFTY 24,052 ▼ 0.66%BANK NIFTY 57,462 ▼ 1.15%NIFTY IT 28,725 ▼ 1.00%NIFTY PHARMA 25,907 ▲ 1.03%NUVOCO 341 ▲ 7.85%AEGISVOPAK 281 ▼ 7.47%BIOCON 437 ▲ 6.41%CONCOR 493 ▲ 6.29%NEWGEN 554 ▼ 6.11%THERMAX 4,380 ▼ 6.09%WELSPUNLIV 165 ▼ 5.51%AEGISLOG 1,222 ▼ 5.50%ADANIPOWER 226 ▲ 4.97%MRPL 157 ▼ 4.72%

Morning brief · Wednesday, 15 July 2026

Keswani Haresh takes ₹370 crore Kama Holdings stake

Market pulse

Indian markets faltered as weakness in banking and technology stocks pulled the Nifty down to close at 24,052. Strength in the pharmaceutical sector, led by a sharp rally in Biocon, was not enough to offset the broader decline, which saw notable losses in stocks like Aegisvopak and Newgen.

From the investor's mind

One post worth your time, explained

@soicfinance · on X

Ishmohit Arora of SOIC notes a significant resurgence in the domestic pharmaceutical sector, highlighting that growth is returning in a big way. The Q1 Indian Pharmaceutical Market (IPM) data indicates a broad-based acceleration in domestic formulations, primarily driven by strong volume growth. This acceleration is particularly pronounced in chronic therapies, which continue to outperform other segments. Arora's key takeaway is that the domestic pharma market is experiencing a robust pickup in growth, propelled by these underlying factors.

Yesterday's big moves